Role of oxygen free radical formation in the mechanism of menogaril resistance in multidrug resistant tumor cells
- PMID: 2168296
- DOI: 10.1016/0009-2797(90)90036-m
Role of oxygen free radical formation in the mechanism of menogaril resistance in multidrug resistant tumor cells
Abstract
The mechanisms of action and resistance to menogaril, a clinically active anthracycline antitumor drug, were evaluated in sensitive and doxorubicin-selected multidrug resistant human breast tumor (MCF-7) cell lines. While MCF-7/ADRR cells were highly resistant (250-500-fold) to doxorubicin, they displayed only marginal resistance (10-fold) to menogaril. In contrast to doxorubicin, the mechanism of resistance to menogaril in these cells does not involve differential inhibition of DNA synthesis as measured by thymidine incorporation. P-170-glycoprotein-dependent drug transport did not contribute to resistance as there was no difference in the accumulation and retention of menogaril by sensitive and resistant cell lines. However, there was a 2-fold decrease in oxygen free radical formation in the resistant cells, compared to sensitive cells, in the presence of menogaril. Since resistant cells contain 12-fold higher glutathione peroxidase activity than the parental sensitive cells, the detoxification of hydrogen peroxide may be responsible for the decreased free radical formation and thus, may play a role in the resistance to menogaril.
Similar articles
-
In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.Cancer Res. 1989 Aug 1;49(15):4098-102. Cancer Res. 1989. PMID: 2472873
-
P388 leukaemia cells resistant to the anthracycline menogaril lack multidrug resistant phenotype.Br J Cancer. 1990 Sep;62(3):378-84. doi: 10.1038/bjc.1990.302. Br J Cancer. 1990. PMID: 2145026 Free PMC article.
-
Menogaril, an anthracycline compound with a novel mechanism of action: cellular pharmacology.Jpn J Cancer Res. 1990 Aug;81(8):842-9. doi: 10.1111/j.1349-7006.1990.tb02654.x. Jpn J Cancer Res. 1990. PMID: 2144516 Free PMC article.
-
Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.J Clin Pharmacol. 1986 Sep-Oct;26(7):491-509. doi: 10.1002/j.1552-4604.1986.tb02942.x. J Clin Pharmacol. 1986. PMID: 2944917 Review.
-
The biochemical pharmacology of nogalamycin and its derivatives.Pharmacol Ther. 1991;51(2):239-55. doi: 10.1016/0163-7258(91)90080-6. Pharmacol Ther. 1991. PMID: 1838416 Review.
Cited by
-
Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukemia.Invest New Drugs. 1993 Nov;11(4):313-22. doi: 10.1007/BF00874430. Invest New Drugs. 1993. PMID: 8157473 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical